Alliance Foundation Trials

• NCT05408026

  Phase 1/2, Withdrawn, 0 people, 7 Jun 2022

• NCT05207709

  Collaborator, Phase 3, Terminated, 61 people, 26 Jan 2022

• NCT05128773

  Collaborator, Phase 3, Terminated, 3 people, 22 Nov 2021

• NCT04486352

  Phase 1/2, Recruiting, 148 people, 24 Jul 2020

• NCT04009109

  Phase 2, Active, not recruiting, 79 people, 5 Jul 2019

• NCT03702725

  Phase 1, Completed, 14 people, 11 Oct 2018

• NCT03498716

  Collaborator, Phase 3, Terminated, 2,199 people, 17 Apr 2018

• Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

  Phase 2, Active, not recruiting, 39 people, 27 Mar 2018

• NCT03009981

  Phase 3, Completed, 504 people, 4 Jan 2017

• NCT02947685

  Phase 3, Active, not recruiting, 518 people, 28 Oct 2016

• NCT02591615

  Phase 2, Completed, 91 people, 29 Oct 2015

• NCT02513394

  Phase 3, Active, not recruiting, 5,796 people, 31 Jul 2015

Sources: clinicaltrials.gov